HVO.L

hVIVO plc
hVIVO PLC - Positive results from RSV human challenge trial
7th October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0032H
hVIVO PLC
07 October 2024
 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Positive results from RSV antiviral human challenge trial conducted by hVIVO

Larger human challenge trial provides valuable insights for candidate development

 

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals ("Enanta"), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus ("RSV") human challenge trial ("HCT") in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate.

 

EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has made impressive strides, achieving U.S. Food and Drug Administration (FDA) Fast Track designation. The topline results from the HCT involving 142 healthy adult volunteers demonstrate the effectiveness of EDP-323. With participants split into three cohorts (47 receiving a high dose, 47 receiving a low dose and 47 receiving a placebo), the study showed that EDP-323 was generally safe, well-tolerated, and demonstrated a rapid and sustained antiviral effect. The results show an 85-87% reduction in viral load area under the curve (AUC) by qRT-PCR (p<0.0001), a 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001), and a 66-78% reduction of total clinical symptoms score AUC (p<0.0001) compared to placebo.

 

These positive results highlight the significant role human challenge trials play in accelerating efficacy data collection and reducing the risks associated with later stage clinical development. With three decades of experience and expertise in safely conducting human challenge studies, hVIVO is proud to support groundbreaking research like this across a range of respiratory viruses, including RSV, influenza, human rhinovirus (HRV - common cold virus), and COVID-19. The Company looks forward to seeing continued success for Enanta and EDP-323 in the future.

 

Enanta's full announcement is available here. EDP-323 is Enanta's second RSV candidate. Zelicapavir (EDP-938), Enanta's first candidate, has already shown impressive results in an earlier RSV HCT and is in later stage clinical development.

 

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "Enanta's trial demonstrates the depth of actionable insights a comprehensive human challenge trial can provide. We congratulate Enanta on these impressive results, which mark a significant step forward in the development of new medicines to treat respiratory infections such as RSV. Achieving such positive outcomes underscores the potential of this novel RSV treatment to make a meaningful impact on patient care. We are proud to provide world leading human challenge trials to support the development of exciting drug candidates which hold the potential to have a positive impact on global health."

 

For further information please contact:

 

hVIVO plc

+44 (0) 20 7756 1300

Yamin 'Mo' Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer




Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash, Camilla Hume, Harriet Ward


Nigel Birks - Life Science Specialist Sales




Peel Hunt LLP (Joint Broker)

+44 (0)20 7418 8900

James Steel, Dr Christopher Golden




Davy (Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell, Niall Gilchrist




Walbrook PR (Financial PR & IR)

Stephanie Cuthbert, Phillip Marriage,
Louis Ashe-Jepson

+44 (0) 20 7933 8780 or hvivo@walbrookpr.com

+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393

 

Notes to Editors

 

About hVIVO

 

hVIVO plc (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

 

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGIBDGXSGDGSS]]>
TwitterFacebookLinkedIn